CXCR4 mutations have no effect on Waldenstrom patient survival under bortezomib-based treatment. (A) Kaplan-Meier curve of progression-free survival in CXCR4-mutated vs WT Waldenstrom macroglobulinemia patients. (B) Kaplan-Meier curve of overall survival in CXCR4-mutated vs WT Waldenstrom macroglobulinemia patients. (C) Bortezomib 50% inhibitory concentration (IC50; μM) over normalized CXCR4 expression levels in human cell lines. (D) Association of CXCR4 mutation status with levels of CXCR4 expression.